Mr. Hotchkin brings more than 20 years of experience in pharmaceutical commercialization, planning, strategy development, and medical affairs to Clene, where he currently leads commercial planning and strategy development, preclinical translational medicine, and health regulatory authority filings. Prior to joining the company, Mr. Hotchkin was a founding team member at Actelion Pharmaceuticals US, Inc., where he helped launch multiple best-in-class products for orphan disorders. Having spent more than a decade at Actelion, Mr. Hotchkin led the commercialization efforts for the company’s Genetic Business Unit, including clinical development activities which resulted in the doubling of sales for two different pharmaceutical drugs. Among his contributions while at Actelion include the implementation of new market planning activities for the company globally, directing U.S. strategy development and leading marketing activities for multiple medicines. Mr. Hotchkin began his career at Parke-Davis, a subsidiary of Pfizer.